{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:26:16Z","timestamp":1760549176424},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.ijrobp.2011.09.002","type":"journal-article","created":{"date-parts":[[2011,12,30]],"date-time":"2011-12-30T15:22:56Z","timestamp":1325258576000},"page":"e609-e615","source":"Crossref","is-referenced-by-count":17,"title":["Phase II Study of Long-Term Androgen Suppression With Bevacizumab and Intensity-Modulated Radiation Therapy (IMRT) in High-Risk Prostate Cancer"],"prefix":"10.1016","volume":"82","author":[{"given":"Jacqueline","family":"Vuky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huong T.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Douglass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasra","family":"Badiozamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guobin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2011.09.002_bib1","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2154::AID-CNCR13>3.0.CO;2-V","article-title":"An enhanced prognostic system for clinically localized carcinoma of the prostate","volume":"79","author":"Pisansky","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1999.17.1.168","article-title":"Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer","volume":"17","author":"D\u2019Amico","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib3","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.1016\/j.ijrobp.2008.06.834","article-title":"Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study","volume":"72","author":"Bolla","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9327","key":"10.1016\/j.ijrobp.2011.09.002_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib5","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02","volume":"21","author":"Hanks","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0360-3016(02)02857-2","article-title":"High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients","volume":"53","author":"Zelefsky","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-5347(05)65855-7","article-title":"High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer","volume":"166","author":"Zelefsky","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib8","first-page":"289","article-title":"Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy","volume":"3","author":"Khil","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2008.05.020","volume":"73","author":"Rosenthal","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.urolonc.2005.11.022","article-title":"Current status of anti-angiogenesis therapy for prostate cancer","volume":"24","author":"Jim\u00e9nez","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","article-title":"Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study","volume":"9","author":"Vergis","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00063030-200620030-00007","article-title":"Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer","volume":"20","author":"Lyseng-Williamson","year":"2006","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib13","first-page":"5565","article-title":"Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib14","first-page":"308","article-title":"Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy","volume":"63","author":"Gorski","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib15","first-page":"39","article-title":"Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts","volume":"61","author":"Kozin","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib16","first-page":"2413","article-title":"Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy","volume":"61","author":"Geng","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG\u2013ASTRO Phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib18","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0360-3016(03)00746-6","article-title":"Intrafractional stability of the prostate using a stereotactic radiotherapy technique","volume":"57","author":"Madsen","year":"2003","journal-title":"J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ijrobp.2006.10.026","article-title":"Multi-institutional clinical experience with the Calypso system in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy","volume":"67","author":"Kupelian","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl.","key":"10.1016\/j.ijrobp.2011.09.002_bib20","first-page":"18s","volume":"28","author":"Kelly","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/0973-1482.52789","article-title":"Normal tissue complication probability: Does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma","volume":"5","author":"Basu","year":"2009","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijrobp.2005.07.970","article-title":"Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose","volume":"64","author":"Pollack","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib23","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ijrobp.2007.01.067","article-title":"Hypofractionated intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic Experience","volume":"68","author":"Kupelian","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ijrobp.2004.11.028","article-title":"Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V","volume":"62","author":"Michalski","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib25","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial factor (VEGF) and vascular endothelial factor receptor (VEGFR) targeting angiogenesis inhibitors","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib26","doi-asserted-by":"crossref","unstructured":"Crane CH, Ellis LM, Xiong H, et\u00a0al. Preliminary results of a phase I study of rhuMab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP) [Abstract]. Presented at the January 2004 Gastrointestinal Cancers Symposium in San Francisco, CA.","DOI":"10.1016\/S1359-6349(03)91007-X"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib27","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoeitin-1 and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib28","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","article-title":"Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors","volume":"64","author":"Tong","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib29","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijrobp.2011.09.002_bib30","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-06-2441","article-title":"Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization","volume":"13","author":"Dings","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301611031786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301611031786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T23:24:02Z","timestamp":1640301842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301611031786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0360301611031786"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2011.09.002","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}